ZACHARY ROBBINS: Open Payments
NPI 1104457613 · CHARLESTON, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$937 in 47 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $319 · 2025 $937
Food & beverage: $937
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $128 |
| Lilly USA, LLC | 7 | $114 |
| ABBVIE INC. | 6 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Exact Sciences Corporation | 2 | $51 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| ViiV Healthcare Company | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Corcept Therapeutics | 1 | $31 |
Products named: MOUNJARO, TRINTELLIX, CAPLYTA, Ozempic, VRAYLAR, The Cologuard Plus Collection Kit, APRETUDE, QULIPTA.
Industry payments across SC — which companies pay providers there.
